ICPT — Intercept Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $793.52m
- $713.07m
- $285.71m
- 57
- 14
- 79
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.47 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.75 | ||
| Price to Tang. Book | 11.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.59 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.32% | ||
| Return on Equity | n/a | ||
| Operating Margin | -51.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 179.8 | 252 | 233.97 | 260.75 | 285.71 | 331.15 | 361.25 | 16.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.
Directors
- Paolo Fundaro NEC (47)
- Jerome Durso PRE (53)
- Andrew Saik CFO (51)
- Lisa Bright CEX (53)
- David Ford CHO (53)
- Linda Richardson EVP (57)
- Christian Weyer EVP (52)
- Gail Cawkwell SVP (59)
- Rocco Venezia CAO (45)
- Gino Santini LED (65)
- Srinivas Akkaraju IND
- Luca Benatti IND (60)
- Daniel Bradbury IND (60)
- Keith Gottesdiener IND
- Nancy Miller-Rich IND (62)
- Dagmar Rosa-bjorkeson IND (57)
- Glenn Sblendorio IND (65)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 4th, 2002
- Public Since
- October 11th, 2012
- No. of Shareholders
- 72
- No. of Employees
- 341
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 41,808,235
- Address
- 305 Madison Avenue, MORRISTOWN, 07960
- Web
- https://www.interceptpharma.com/
- Phone
- +1 6467471000
- Auditors
- KPMG LLP
Upcoming Events for ICPT
Q1 2024 Intercept Pharmaceuticals Inc Earnings Release
Similar to ICPT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Intercept Pharmaceuticals share price?
As of Today at 18:11 UTC, shares in Intercept Pharmaceuticals are trading at $18.98. This share price information is delayed by 15 minutes.
How has the Intercept Pharmaceuticals share price performed this year?
Shares in Intercept Pharmaceuticals last closed at $18.98 and the price had moved by +25.95% over the past 365 days. In terms of relative price strength the Intercept Pharmaceuticals share price has outperformed the S&P500 Index by +8.96% over the past year.
What are the analyst and broker recommendations for Intercept Pharmaceuticals?
The overall consensus recommendation for Intercept Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Intercept Pharmaceuticals dividend yield?
Intercept Pharmaceuticals does not currently pay a dividend.
Does Intercept Pharmaceuticals pay a dividend?
Intercept Pharmaceuticals does not currently pay a dividend.
When does Intercept Pharmaceuticals next pay dividends?
Intercept Pharmaceuticals does not currently pay a dividend.
How do I buy Intercept Pharmaceuticals shares?
To buy shares in Intercept Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Intercept Pharmaceuticals?
As of the previous close price of $18.98, shares in Intercept Pharmaceuticals had a market capitalisation of $793.52m.
Where are Intercept Pharmaceuticals shares listed?
Here are the trading details for Intercept Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ICPT
What kind of share is Intercept Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Intercept Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Intercept Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in Intercept Pharmaceuticals is $19.00. That is 0.11% above the last closing price of $18.98.
Analysts covering Intercept Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.31 for the next financial year.
What is the trend in the Intercept Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intercept Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +11.52%.
As of the last closing price of $18.98, shares in Intercept Pharmaceuticals were trading +29.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Intercept Pharmaceuticals PE Ratio?
The Intercept Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 12.47. The shares last closed at $18.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Intercept Pharmaceuticals?
Intercept Pharmaceuticals' management team is headed by:
- Paolo Fundaro - NEC
- Jerome Durso - PRE
- Andrew Saik - CFO
- Lisa Bright - CEX
- David Ford - CHO
- Linda Richardson - EVP
- Christian Weyer - EVP
- Gail Cawkwell - SVP
- Rocco Venezia - CAO
- Gino Santini - LED
- Srinivas Akkaraju - IND
- Luca Benatti - IND
- Daniel Bradbury - IND
- Keith Gottesdiener - IND
- Nancy Miller-Rich - IND
- Dagmar Rosa-bjorkeson - IND
- Glenn Sblendorio - IND